Menstrual migraine: a double-blind trial of percutaneous estradiol

Gynecol Endocrinol. 1988 Jun;2(2):113-20. doi: 10.3109/09513598809023619.

Abstract

The present study investigated whether administration of percutaneous estradiol for the 7 days encompassing menstruation (the paramenstruum) would be effective in alleviating menstrual migraine. The study was a double-blind cross-over placebo comparison of percutaneous estradiol in gel form. Twenty-two women who suffered from regular recurring menstrual migraine were studied during 2 assessment menstrual cycles, 4 treatment cycles (2 of estradiol gel, 2 of placebo gel), and 1 follow-up (no treatment) cycle. Women completed daily records of the occurrence and severity of migraine and medication used. Eighteen women completed the study. There was a significant reduction in the frequency of migraine in the paramenstruum and in the amount of medication taken during use of percutaneous estradiol. Women expressed a significant preference for continuation of therapy with percutaneous estradiol.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Estradiol / administration & dosage
  • Estradiol / adverse effects
  • Estradiol / therapeutic use*
  • Female
  • Gels
  • Humans
  • Menstrual Cycle*
  • Migraine Disorders / drug therapy*
  • Random Allocation

Substances

  • Gels
  • Estradiol